{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:08:45Z","timestamp":1779433725284,"version":"3.53.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematopathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions (M\/LN-eo-TK) are diverse, with most cases showing a combination of lymphoblastic leukemia\/lymphoma and myeloproliferative features. Various tyrosine kinase fusion genes have been identified, including FLT3 fusions. RNA based next generation sequencing studies offer an effective approach to detect such pathogenic fusion genes, including the novel SSBP2::FLT3 fusion described here. Timely identification of this fusion gene led to targeted management of our patient, who achieved complete resolution of his FDG-avid lymphadenopathy only after the addition of gilteritinib. Two years after successful bone marrow transplant, the patient remains in complete remission. Clinicians and pathologists should have a low index of suspicion for a M\/LN-eo-TK when evaluating patients with and without unexplained eosinophilia in the context of extramedullary lymphoid or myeloid disease or unusual myeloproliferative disorders.<\/jats:p>","DOI":"10.1007\/s12308-026-00702-9","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:50:35Z","timestamp":1779432635000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Myeloid\/lymphoid neoplasm with FLT3 gene fusion: report of a case with a novel t(5;13)(q13;q12) SSBP2::FLT3 fusion"],"prefix":"10.1007","volume":"19","author":[{"given":"James R.","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Astbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Bosler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heesun J.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Sobecks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Owczarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"6","key":"702_CR1","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/his.15021","volume":"83","author":"L Saft","year":"2023","unstructured":"Saft L, Kvasnicka HM, Boudova L, Gianelli U, Lazzi S, Rozman M (2023) Myeloid\/lymphoid neoplasms with eosinophilia and tyrosine kinase fusion genes: a workshop report with focus on novel entities and a literature review including paediatric cases. Histopathology 83(6):829\u2013849","journal-title":"Histopathology"},{"issue":"1","key":"702_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00428-022-03402-8","volume":"482","author":"A Tzankov","year":"2023","unstructured":"Tzankov A, Reichard KK, Hasserjian RP, Arber DA, Orazi A, Wang SA (2023) Updates on eosinophilic disorders. Virchows Arch 482(1):85\u201397","journal-title":"Virchows Arch"},{"issue":"8","key":"702_CR3","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1002\/ajh.26966","volume":"98","author":"SA Wang","year":"2023","unstructured":"Wang SA, Orazi A, Gotlib J, Reiter A, Tzankov A, Hasserjian RP, Arber DA, Tefferi A (2023) The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol 98(8):1286\u20131306","journal-title":"Am J Hematol"},{"key":"702_CR4","unstructured":"WHO (2008) classification of tumours of haematopoietic and lymphoid tissues., 4th ed., IARC Press, Lyon"},{"key":"702_CR5","unstructured":"WHO (2017) classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon"},{"key":"702_CR6","first-page":"p. 832","volume-title":"The international consensus classification of myeloid and lymphoid neoplasms","author":"DA Arber","year":"2025","unstructured":"Arber DA, Borowitz MJ, Cook JR, De Leval L, Goodlad JR, Hasserjian RP, King RL, Kvasnicka HM, Orazi A (2025) The international consensus classification of myeloid and lymphoid neoplasms. Wolters Kluwer, Philadelphia, PA, p 832"},{"key":"702_CR7","unstructured":"Haematolymphoid Tumours (2024) 5th ed., International Agency for Research on Cancer, Lyon"},{"issue":"2","key":"702_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcp\/aqaa208","volume":"155","author":"O Pozdnyakova","year":"2021","unstructured":"Pozdnyakova O, Orazi A, Kelemen K, King R, Reichard KK, Craig FE, Quintanilla-Martinez L, Rimsza L, George TI, Horny HP, Wang SA (2021) Myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangements of PDGFRA, PDGFRB, or FGFR1 or with PCM1-JAK2. Am J Clin Pathol 155(2):160\u2013178","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"702_CR9","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s00428-023-03693-5","volume":"484","author":"J Schoelinck","year":"2024","unstructured":"Schoelinck J, Gervasoni J, Guillermin Y, Beillard E, Pissaloux D, Chassagne-Clement C (2024) T cell phenotype and lack of eosinophilia are not uncommon in extramedullary myeloid\/lymphoid neoplasms with ETV6::FLT3 fusion: a case report and review of the literature. Virchows Arch 484(5):853\u2013857","journal-title":"Virchows Arch"},{"issue":"16","key":"702_CR10","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1182\/blood.2023022417","volume":"145","author":"A Reiter","year":"2025","unstructured":"Reiter A, Metzgeroth G, Cross NCP (2025) How I diagnose and treat myeloid\/lymphoid neoplasms with tyrosine kinase gene fusions. Blood 145(16):1758\u20131768","journal-title":"Blood"},{"issue":"9","key":"702_CR11","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1038\/s41379-021-00817-7","volume":"34","author":"G Tang","year":"2021","unstructured":"Tang G, Tam W, Short NJ, Bose P, Wu D, Hurwitz SN, Bagg A, Rogers HJ, Hsi ED, Quesada AE, Wang W, Miranda RN, Bueso-Ramos CE, Medeiros LJ, Nardi V, Hasserjian RP, Arber DA, Orazi A, Foucar K, Wang SA (2021) Myeloid\/lymphoid neoplasms with FLT3 rearrangement. Mod Pathol 34(9):1673\u20131685","journal-title":"Mod Pathol"},{"issue":"13","key":"702_CR12","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1182\/blood.2020008536","volume":"137","author":"C Schwab","year":"2021","unstructured":"Schwab C, Roberts K, Boer JM, Gohring G, Steinemann D, Vora A, Macartney C, Hough R, Thorn Z, Dillon R, Escherich G, Cazzaniga G, Schlegelberger B, Loh M, den Boer ML, Moorman AV, Harrison CJ (2021) SSBP2-CSF1R is a recurrent fusion in B-lineage acute lymphoblastic leukemia with diverse genetic presentation and variable outcome. Blood 137(13):1835\u20131838","journal-title":"Blood"},{"issue":"10","key":"702_CR13","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1002\/gcc.20585","volume":"47","author":"JL Poitras","year":"2008","unstructured":"Poitras JL, Dal Cin P, Aster JC, Deangelo DJ, Morton CC (2008) Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia. Genes Chromosomes Cancer 47(10):884\u2013889","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"702_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003997","volume":"9","author":"ZK Atak","year":"2013","unstructured":"Atak ZK, Gianfelici V, Hulselmans G, De Keersmaecker K, Devasia AG, Geerdens E, Mentens N, Chiaretti S, Durinck K, Uyttebroeck A, Vandenberghe P, Wlodarska I, Cloos J, Foa R, Speleman F, Cools J, Aerts S (2013) Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet 9(12):e1003997","journal-title":"PLoS Genet"},{"key":"702_CR15","unstructured":"Dessen P\u00a0 (2025) SSBP2 (Single Stranded DNA Binding Protein 2). Accessed 8\/1\/2025. http:\/\/atlasgeneticsoncology.org\/gene\/46000\/ssbp2-(single-stranded-dna-binding-protein-2"}],"container-title":["Journal of Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-026-00702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12308-026-00702-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12308-026-00702-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T06:50:37Z","timestamp":1779432637000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12308-026-00702-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1007\/s12308-026-00702-9","relation":{},"ISSN":["1865-5785"],"issn-type":[{"value":"1865-5785","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"2 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"For this type of study consent for publication is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"24"}}